Type 1 Diabetes Clinical Trials
Current clinical trials for adults with type 1 diabetes are exploring treatments to restore beta cell function, stem cell therapy, and new medications for kidney disease. See if you're eligible to enroll.
Researchers are constantly evaluating new treatments and technologies that could help people with type 1 diabetes live happy, healthier lives.
Participating in a clinical trial can go a long way toward advancing treatments and health outcomes for people with diabetes.
Here are several trials specifically recruiting people with type 1 diabetes:
This study is investigating whether Vertex’s VX-264, an encapsulated stem cell therapy, can safely restore insulin-producing islet cell function in people with type 1 diabetes without the need for lifelong immunosuppressive medication.
A clinical trial is recruiting people recently diagnosed with type 1 diabetes to see if the investigational drug Diamyd preserves insulin-producing cells as well as improves time in range.
A global study is investigating the effectiveness of an eating disorder prevention program to help younger people with type 1 diabetes reduce body image concerns and improve blood glucose control.
The FINE-ONE trial, which is investigating Kerendia (finerenone) in adults with type 1 diabetes, will begin in March 2024. Despite the high prevalence of kidney disease in people with type 1 diabetes, there are few available treatments approved in this population.
More clinical trials to watch out for:
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes (ZONE): This study will investigate a new experimental drug, ZT-01, which aims to prevent nighttime low blood sugar in adults with type 1 diabetes who have a history of nocturnal hypoglycemia.
Teplizumab in Pediatric Stage 2 Type 1 Diabetes (PETITE-T1D): Researchers are investigating the safety and absorption of Tzield (teplizumab) in a small study of children (ages 0-8) with stage 2 type 1 diabetes.
Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes (T1-DISCO): Researchers in Colorado will study how the GLP-1 receptor agonist Wegovy (semaglutide) affects heart and kidney function as well as insulin sensitivity in adults with type 1 diabetes.
Verapamil SR in Adults With Type 1 Diabetes (Ver-A-T1D): This trial, based in Europe, aims to confirm that the experimental drug verapamil helps preserve beta-cell function over a 12-month period in adults with type 1 diabetes.
Learn more about type 1 diabetes research and treatments here: